A simple additive staging system for newly diagnosed multiple myeloma

被引：73

作者：

Abdallah, Nadine H. ^{[1
]}

Binder, Moritz ^{[1
]}

Rajkumar, S. Vincent ^{[1
]}

Greipp, Patricia T. ^{[2
]}

Kapoor, Prashant ^{[1
]}

Dispenzieri, Angela ^{[1
]}

Gertz, Morie A. ^{[1
]}

Baughn, Linda B. ^{[2
]}

Lacy, Martha Q. ^{[1
]}

Hayman, Suzanne R. ^{[1
]}

Buadi, Francis K. ^{[1
]}

Dingli, David ^{[1
]}

Go, Ronald S. ^{[1
]}

Hwa, Yi L. ^{[1
]}

Fonder, Amie L. ^{[1
]}

Hobbs, Miriam A. ^{[1
]}

Lin, Yi ^{[1
]}

Leung, Nelson ^{[1
,3
]}

Kourelis, Taxiarchis ^{[1
]}

Warsame, Rahma ^{[1
]}

Siddiqui, Mustaqeem A. ^{[1
]}

Kyle, Robert A. ^{[1
]}

Bergsagel, P. Leif ^{[4
]}

Fonseca, Rafael ^{[4
]}

Ketterling, Rhett P. ^{[1
]}

Kumar, Shaji K. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55902 USA

[2] Dept Lab Med & Pathol, Rochester, MN USA

[3] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN USA

[4] Mayo Clin, Div Hematol, Phoenix, AZ USA

来源：

BLOOD CANCER JOURNAL | 2022年 / 12卷 / 01期

关键词：

PROGNOSTIC-FACTOR; GENE-EXPRESSION; CHROMOSOME-13; ABNORMALITIES; DELETION;

D O I：

10.1038/s41408-022-00611-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Risk stratification in multiple myeloma is important for prognostication, patient selection for clinical trials, and comparison of treatment approaches. We developed and validated a staging system that incorporates additional FISH abnormalities not included in the R-ISS and reflects the additive effects of co-occurring high-risk disease features. We first evaluated the prognostic value of predefined cytogenetic and laboratory abnormalities in 2556 Mayo Clinic patients diagnosed between February 2004 and June 2019. We then used data from 1327 patients to develop a risk stratification model and validated this in 502 patients enrolled in the MMRF CoMMpass study. On multivariate analysis, high-risk IgH translocations [risk ratio (RR): 1.7], 1q gain/amplification (RR: 1.4), chromosome17 abnormalities (RR: 1.6), ISS III (RR: 1.7), and elevated LDH (RR: 1.3) were independently associated with decreased overall survival (OS). Among 1327 evaluable patients, OS was 11.0 (95% CI: 9.2-12.6), 7.0 (95% CI: 6.3-9.2), and 4.5 (95% CI: 3.7-5.2) years in patients with 0 (stage I), 1 (stage II), and >= 2 (stage III) high-risk factors, respectively. In the MMRF cohort, median OS was 7.8 (95% CI: NR-NR), 6.0 (95% CI: 5.7-NR), and 4.3 (95% CI: 2.7-NR) years in the 3 groups, respectively (P < 0.001). This 5-factor, 3-tier system is easy to implement in practice and improves upon the current R-ISS.

引用

页数：9

共 37 条

[1] Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma [J].

Abdallah, Nadine ;

Baughn, Linda B. ;

Rajkumar, S. Vincent ;

Kapoor, Prashant ;

Gertz, Morie A. ;

Dispenzieri, Angela ;

Lacy, Martha Q. ;

Hayman, Suzanne R. ;

Buadi, Francis K. ;

Dingli, David ;

Go, Ronald S. ;

Hwa, Yi L. ;

Fonder, Amie ;

Hobbs, Miriam ;

Lin, Yi ;

Leung, Nelson ;

Kourelis, Taxiarchis ;

Warsame, Rahma ;

Siddiqui, Mustaqeem ;

Lust, John ;

Kyle, Robert A. ;

Ketterling, Rhett ;

Bergsagel, Leif ;

Greipp, Patricia ;

Kumar, Shaji K. .

CLINICAL CANCER RESEARCH, 2020, 26 (24) :6581-6588

[2] Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities [J].

Abdallah, Nadine ;

Greipp, Patricia ;

Kapoor, Prashant ;

Gertz, Morie A. ;

Dispenzieri, Angela ;

Baughn, Linda B. ;

Lacy, Martha Q. ;

Hayman, Suzanne R. ;

Buadi, Francis K. ;

Dingli, David ;

Go, Ronald S. ;

Hwa, Yi L. ;

Fonder, Amie ;

Hobbs, Miriam ;

Lin, Yi ;

Leung, Nelson ;

Kourelis, Taxiarchis ;

Warsame, Rahma ;

Siddiqui, Mustaqeem ;

Lust, John ;

Kyle, Robert A. ;

Bergsagel, Leif ;

Ketterling, Rhett ;

Rajkumar, S. Vincent ;

Kumar, Shaji K. .

BLOOD ADVANCES, 2020, 4 (15) :3509-3519

[3] Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project [J].

Avet-Loiseau, H. ;

Durie, B. G. M. ;

Cavo, M. ;

Attal, M. ;

Gutierrez, N. ;

Haessler, J. ;

Goldschmidt, H. ;

Hajek, R. ;

Lee, J. H. ;

Sezer, O. ;

Barlogie, B. ;

Crowley, J. ;

Fonseca, R. ;

Testoni, N. ;

Ross, F. ;

Rajkumar, S. V. ;

Sonneveld, P. ;

Lahuerta, J. ;

Moreau, P. ;

Morgan, G. .

LEUKEMIA, 2013, 27 (03) :711-717

[4] Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma [J].

Binder, M. ;

Rajkumar, S. V. ;

Ketterling, R. P. ;

Greipp, P. T. ;

Dispenzieri, A. ;

Lacy, M. Q. ;

Gertz, M. A. ;

Buadi, F. K. ;

Hayman, S. R. ;

Hwa, Y. L. ;

Zeldenrust, S. R. ;

Lust, J. A. ;

Russell, S. J. ;

Leung, N. ;

Kapoor, P. ;

Go, R. S. ;

Gonsalves, W. I. ;

Kyle, R. A. ;

Kumar, S. K. .

BLOOD CANCER JOURNAL, 2017, 7 :e600-e600

[5] Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma [J].

Chiecchio, L. ;

Protheroe, R. K. M. ;

Ibrahim, A. H. ;

Cheung, K. L. ;

Rudduck, C. ;

Dagrada, G. P. ;

Cabanas, E. D. ;

Parker, T. ;

Nightingale, M. ;

Wechalekar, A. ;

Orchard, K. H. ;

Harrison, C. J. ;

Cross, N. C. P. ;

Morgan, G. J. ;

Ross, F. M. .

LEUKEMIA, 2006, 20 (09) :1610-1617

[6] Prognostic factors for hyperdiploid-myeloma:: effects of chromosome 13 deletions and IgH translocations [J].

Chng, W ;

Santana-Dávila, R ;

Van Wier, S ;

Ahmann, GJ ;

Jalal, SM ;

Bergsagel, PL ;

Chesi, M ;

Trendle, MC ;

Jacobus, S ;

Blood, E ;

Oken, MM ;

Henderson, K ;

Kyle, RA ;

Gertz, MA ;

Lacy, MQ ;

Dispenzieri, A ;

Greipp, PR ;

Fonseca, R .

LEUKEMIA, 2006, 20 (05) :807-813

[7] IMWG consensus on risk stratification in multiple myeloma [J].

Chng, W. J. ;

Dispenzieri, A. ;

Chim, C-S ;

Fonseca, R. ;

Goldschmidt, H. ;

Lentzsch, S. ;

Munshi, N. ;

Palumbo, A. ;

Miguel, J. S. ;

Sonneveld, P. ;

Cavo, M. ;

Usmani, S. ;

Durie, B. G. M. ;

Avet-Loiseau, H. .

LEUKEMIA, 2014, 28 (02) :269-277

[8] Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy [J].

Cho, Hyungwoo ;

Yoon, Dok Hyun ;

Lee, Jung Bok ;

Kim, Sung-Yong ;

Moon, Joon Ho ;

Do, Young Rok ;

Lee, Jae Hoon ;

Park, Yong ;

Lee, Ho Sup ;

Eom, Hyeon Seok ;

Shin, Ho-Jin ;

Min, Chang-Ki ;

Kim, Jin Seok ;

Jo, Jae-Cheol ;

Kang, Hye Jin ;

Mun, Yeung-Chul ;

Lee, Won Sik ;

Lee, Je-Jung ;

Suh, Cheolwon ;

Kim, Kihyun .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (12) :1280-1286

[9] Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) [J].

Durie, Brian G. M. ;

Hoering, Antje ;

Sexton, Rachael ;

Abidi, Muneer H. ;

Epstein, Joshua ;

Rajkumar, S. Vincent ;

Dispenzieri, Angela ;

Kahanic, Stephen P. ;

Thakuri, Mohan C. ;

Reu, Frederic J. ;

Reynolds, Christopher M. ;

Orlowski, Robert Z. ;

Barlogie, Bart .

BLOOD CANCER JOURNAL, 2020, 10 (05)

[10] Clinical and biologic implications of recurrent genomic aberrations in myeloma [J].

Fonseca, R ;

Blood, E ;

Rue, M ;

Harrington, D ;

Oken, MM ;

Kyle, RA ;

Dewald, GW ;

Van Ness, B ;

Van Wier, SA ;

Henderson, KJ ;

Bailey, RJ ;

Greipp, PR .

BLOOD, 2003, 101 (11) :4569-4575

← 1 2 3 4 →